Key facts
- Origin Peptides’s last known valuation is $910K (Mar 2025).
- It has raised $400K; the latest was Later Stage VC ($400K) in Mar 2025.
- Notable investors include Scottish Enterprise, General Inception, Pioneer Group.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Origin Peptides
- ·The full record, as it builds
Funding rounds
No funding rounds for Origin Peptides are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Origin Peptides
Developer of custom peptide products designed for research and pharmaceutical applications. The company's utilizes a novel one-pot aqueous synthesis method, which eliminates the need for hazardous organic solvents and iterative process steps, thereby reducing reaction volumes, improving the Product Manufacturing Index, and cost-effective production of these biological molecules, enabling the biotechnology and pharmaceutical market to develop new therapies and applications with a reduced environmental footprint.
- Sector
- Business Products and Services (B2B)
- HQ
- Linlithgow, United Kingdom
- Founded
- 2018
- Employees
- 7
- Website
- originpeptides.com/
- Ownership
- Privately Held (backing)
Origin Peptides doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Origin Peptides shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Origin Peptides in its N-PORT filings yet. We sweep new filings monthly.